keyword
MENU ▼
Read by QxMD icon Read
search

Timolol

keyword
https://www.readbyqxmd.com/read/29452108/effect-of-brimonidine-an-%C3%AE-2-adrenergic-agonist-on-human-meibomian-gland-epithelial-cells
#1
Xi Han, Yang Liu, Wendy R Kam, David A Sullivan
We recently discovered that the anti-glaucoma pharmaceuticals timolol, a β adrenergic antagonist, and pilocarpine, a cholinergic compound, negatively influence the morphology, proliferative capacity and survival of human meibomian gland epithelial cells (HMGECs). We hypothesize that another class of anti-glaucoma drugs, the α2 adrenergic agonists, also acts directly on HMGECs to affect their structure and function. We tested this hypothesis. Immortalized (i) HMGECs were cultured with brimonidine, as well as clonidine (α2 agonist), phenylephrine (α1 agonist), RX821002 (inverse α2 agonist) and MK912 (neutral α2 agonist) for up to 7 days...
February 13, 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29423783/peyronie-s-disease-and-dupuytren-s-contracture-secondary-to-topical-timolol
#2
Huw Oliphant, Pieter Gouws
INTRODUCTION: Topical beta-blockers are a proven and safe medication used in the treatment of glaucoma and ocular hypertension. Local and systemic side effects are, however, well documented. Systemic side effects can include severe cardio-respiratory impairment, endocrine dysfunction, as well as headache and hyper-somnolence. Disorders involving fibrosis such as Peyronie's disease, Dupuytren's contracture, and retroperitoneal fibrosis are rarely described in the literature. CASE REPORT: We describe a case of a 55-year-old male patient undergoing treatment for ocular hypertension with topical timolol 0...
February 8, 2018: International Ophthalmology
https://www.readbyqxmd.com/read/29412149/topical-timolol-for-an-iris-hemangioma
#3
Ravali Gummi, Erin D Stahl, Justin D Marsh
No abstract text is available yet for this article.
February 2, 2018: Journal of AAPOS: the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
https://www.readbyqxmd.com/read/29401160/meibomian-gland-features-and-conjunctival-goblet-cell-density-in-glaucomatous-patients-controlled-with-prostaglandin-timolol-fixed-combinations-a-case-control-cross-sectional-study
#4
Luca Agnifili, Rodolfo Mastropasqua, Vincenzo Fasanella, Lorenza Brescia, Barbara Scatena, Francesco Oddone, Leonardo Mastropasqua
PURPOSE: To investigate, using in vivo confocal microscopy (IVCM), the Meibomian gland (MG) features and conjunctival goblet cell density (GCD) in glaucomatous patients controlled with prostaglandin/timolol fixed combinations (PTFCs). METHODS: In this cross-sectional study, sixty Caucasian patients treated with PTFCs, fifteen with latanoprost+timolol (L+T) unfixed combination, and fifteen controls were enrolled. Patients underwent the Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (BUT), corneal staining, Schirmer test I (STI), and IVCM of MGs and goblet cells (GCs)...
February 2, 2018: Journal of Glaucoma
https://www.readbyqxmd.com/read/29391124/eye-drop-dispenser-type-and-medication-possession-ratio-in-patients-with-glaucoma-single-use-containers-versus-multiple-use-bottles
#5
Kun-Hoo Na, Chungkwon Yoo, Ji-Hye Park, Yong Yeon Kim
PURPOSE: To determine whether the consumption of topical glaucoma medication is influenced by the type of eye drop dispenser DESIGN: Retrospective cohort study METHODS: We examined 366 patients with open-angle glaucoma or ocular hypertension who were bilaterally treated with 0.0015% tafluprost or 2% dorzolamide/0.5% timolol fixed combination (DTFC). The patients were grouped by the type of dispenser and content of eye drops used: 1) tafluprost in bottles (T-Bottle group); 2) tafluprost in unit-dose pipettes (T-Unit group); 3) DTFC in bottles (C-Bottle group); and 4) DTFC in unit-dose pipettes (C-Unit group)...
January 29, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29373090/the-beta-2-adrenergic-receptor-antagonist-timolol-improves-healing-of-combined-burn-and-radiation-wounds
#6
Huguette Albrecht, Hsin-Ya Yang, Maija Kiuru, Saipiroon Maksaereekul, Blythe Durbin-Johnson, Michael S Wong, Thomas R Stevenson, David M Rocke, R Rivkah Isseroff
In a scenario involving a nuclear detonation during war or a terrorist attack, acute radiation exposure combined with thermal and blast effects results in severe skin injury. Although the cutaneous injury in such a scenario may not be lethal, it may lead to inflammation, delayed wound healing and loss of the skin barrier, resulting in an increased risk of infection. In this study, we tested the potential use of timolol, a beta-adrenergic receptor antagonist, to improve epidermal wound closure after combined burn and radiation injury using an ex vivo human skin culture model...
January 26, 2018: Radiation Research
https://www.readbyqxmd.com/read/29362868/effect-of-topical-timolol-on-response-rate-and-adverse-events-in-infantile-hemangioma-a-meta-analysis
#7
REVIEW
Lei Zheng, Yunling Li
A number of clinical trials evaluated the effect of topical timolol in the treatment of infantile hemangioma and provided inconsistent results. The present study assessed the response rate and adverse events of topical timolol in the treatment of infantile hemangioma. Pubmed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, and Cochrane library were searched until October 2016. Specific inclusion criteria were used to evaluate articles. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated...
January 23, 2018: Archives of Dermatological Research
https://www.readbyqxmd.com/read/29341922/sustained-release-timolol-maleate-loaded-ocusert-based-on-biopolymer-composite
#8
Revathy V Nair, Shefrin S, Akhil Suresh, Anoop K R, Sreeja C Nair
In the present investigation, the effect of timolol maleate loaded ocuserts was studied as an alternative for conventional anti-glaucoma formulation. Ocuserts were prepared using natural polymer sodium alginate and ethyl cellulose. Physico-chemical properties along with drug entrapment efficiency (94-98%), content uniformity (93.1% ± 0.264-98.00% ± 0.321), in vitro drug release (83.42% ± 0.35 at end of 12 hours), ex vivo permeation all showed satisfactory results, which was found to follow zero order kinetics...
January 13, 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29319215/considerations-of-prescribers-and-pharmacists-for-the-use-of-non-selective-%C3%AE-blockers-in-asthma-and-copd-patients-an-explorative-study
#9
Esther Kuipers, Michel Wensing, Peter A G M De Smet, Martina Teichert
RATIONALE, AIMS, AND OBJECTIVES: Despite recommendations in prevailing guidelines to avoid the use of non-selective (NS) β-blockers in patients with asthma or COPD, on average, 10 patients per community pharmacy receive NS β-blockers monthly. The aim of our study was to identify the reasons of prescribers and pharmacists to treat asthma and COPD patients with NS β-blockers. METHODS: Fifty-three community pharmacists in the Netherlands selected patients with actual concurrent use of inhalation medication and NS β-blockers...
January 10, 2018: Journal of Evaluation in Clinical Practice
https://www.readbyqxmd.com/read/29315812/doing-the-math-a-simple-approach-to-topical-timolol-dosing-for-infantile-hemangiomas
#10
Renata Dalla Costa, Brea Prindaville, Karen Wiss
Topical timolol maleate has recently gained popularity as a treatment for superficial infantile hemangiomas, but calculating a safe dose of timolol can be time consuming, which may limit the medication's use in fast-paced clinical environments. This report offers a simplified calculation of the maximum daily safe dosage as 1 drop of medication per kilogram of body weight.
January 9, 2018: Pediatric Dermatology
https://www.readbyqxmd.com/read/29307642/combination-of-ligation-and-timolol-before-surgical-excision-of-pyogenic-granuloma
#11
Yoo Sang Baek, Seung Hwi Kwon, Jiehyun Jeon
No abstract text is available yet for this article.
January 4, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29279659/superior-oblique-myokymia-some-novel-observations
#12
Sanitha Sathyan, Rosemary C Antony
Superior oblique myokymia is a rare condition, characterized by spontaneous rhythmic contractions of the superior oblique muscle and was first described by Duane in 1906. However, the pathophysiology of this condition remains poorly understood even today. A number of medical and surgical treatment modalities have been tried, with variable results. We report a case of superior oblique myokymia in a pregnant female, which could be triggered with flashlight stimulation, and the result of treatment with timolol maleate 0...
July 2017: Middle East African Journal of Ophthalmology
https://www.readbyqxmd.com/read/29260089/neovascularization-of-the-iris-in-retinoschisis
#13
Geraldine R Slean, Arthur D Fu, Judy Chen, Ananda Kalevar
Purpose: To report the association of rubeosis iridis with chronic bullous degenerative peripheral retinoschisis. Observations: A 63-year-old female presented with acute hyphema and neovascularization of the iris in association with elevated intraocular pressure. Posterior segment examination including imaging revealed no vascular occlusion as a potential cause. However, large, peripheral bullous retinoschisis was noted in the right eye. No nonperfusion aside from that seen within the schism detachment, or neovascularization of the retina on wide-field fundus photography or fluorescein angiography was noted...
September 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29260088/acute-hypotony-maculopathy-following-the-initiation-of-a-topical-aqueous-suppressant-in-a-patient-with-a-history-of-panuveitis-without-prior-filtering-surgery
#14
Dagny Zhu, Hossein Ameri, Alena Reznik, Narsing A Rao
Purpose: To report a case of profound hypotony maculopathy as a complication of single-agent glaucoma therapy in a patient with a history of panuveitis without previous filtering surgery. Observations: A 70-year old Hispanic male with a history of resolved bilateral panuveitis, chronic angle closure glaucoma, and pars plana vitrectomy was started on topical timolol 0.5% daily in the left eye for mildly elevated intraocular pressure (15 mmHg). The patient returned 1...
September 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29258748/omega-3-fatty-acids-protect-retinal-neurons-in-the-dba-2j-hereditary-glaucoma-mouse-model
#15
Maria Kalogerou, Panagiotis Kolovos, Ekatherine Prokopiou, Gregory Papagregoriou, Constantinos Deltas, Stavros Malas, Tassos Georgiou
The purpose of this study was to evaluate the neuroprotective effects of omega-3 polyunsaturated fatty acid (ω3-PUFA) supplementation, alone or in combination with timolol eye drops, in a mouse model of hereditary glaucoma. DBA/2J mice (8.5-month-old) were assigned to an ω3-PUFAs + timolol, ω3-PUFAs only, timolol only, or an untreated group. Treated mice received a daily gavage administration of eicosapentaenoic acid (EPA) and docosahexaenoic acid and/or topical instillation of timolol (0.5%) once a day for 3 months...
December 16, 2017: Experimental Eye Research
https://www.readbyqxmd.com/read/29200831/efficacy-and-safety-of-fixed-combination-bimatoprost-timolol-ophthalmic-solution
#16
COMMENT
Suk Bae Moon, Sang Beom Han
No abstract text is available yet for this article.
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29199013/two-phase-3-clinical-trials-comparing-the-safety-and-efficacy-of-netarsudil-to-timolol-in-patients-with-elevated-intraocular-pressure
#17
Janet B Serle, L Jay Katz, Eugene McLaurin, Theresa Heah, Nancy Ramirez-Davis, Dale W Usner, Gary D Novack, Casey C Kopczynski
PURPOSE: To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension. DESIGN: Double-masked, randomized non-inferiority clinical trials. METHODS: After a washout of all pre-study ocular hypotensive medications, eligible patients were randomized to receive netarsudil 0.02%, q.d., timolol 0...
November 30, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29198091/-treatments-for-slowing-the-progression-of-myopia
#18
REVIEW
Nir Erdinest, Yair Morad
Myopia is the most common refractive error and is now endemic over the entire industrial world, particularly in Asia. High myopia is one of the major causes of blindness in the world. Slowing the progress of myopia is possible, the most effective treatment being atropine ophthalmic drops, given in a dose-dependent fashion. Although high-dose atropine (1% and 0.5%) was found to be highly effective in slowing myopia progression, low-dose atropine (0.01%) was found to have the lowest rebound effect (accelerated myopia progression after treatment cessation) and was therefore, the most effective treatment in the long term...
November 2017: Harefuah
https://www.readbyqxmd.com/read/29196953/preservative-free-prostaglandin-analogs-and-prostaglandin-timolol-fixed-combinations-in-the-treatment-of-glaucoma-efficacy-safety-and-potential-advantages
#19
REVIEW
Gábor Holló, Andreas Katsanos, Kostas G Boboridis, Murat Irkec, Anastasios G P Konstas
Glaucoma therapy-related ocular surface disease (OSD) is a serious pathology with a broad spectrum of insidious clinical presentations and complex pathogenesis that undermines long-term glaucoma care. Preservatives, especially benzalkonium chloride (BAK), contained in topical intraocular pressure-lowering medications frequently cause or aggravate OSD in glaucoma. Management of these patients is challenging, and to date often empirical due to the scarcity of controlled long-term clinical trials. Most of the available data are extracted from case series and retrospective analysis...
January 2018: Drugs
https://www.readbyqxmd.com/read/29194198/latanoprostene-bunod-0-024-in-subjects-with-open-angle-glaucoma-or-ocular-hypertension-pooled-phase-3-study-findings
#20
Robert N Weinreb, Jeffrey M Liebmann, Keith R Martin, Paul L Kaufman, Jason L Vittitow
PURPOSE: To compare the diurnal intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT). PATIENTS AND METHODS: Pooled analysis of two phase 3, randomized, multicenter, double-masked, parallel-group, noninferiority trials (APOLLO and LUNAR), each with open-label safety extension phases. Adults with OAG or OHT were randomized 2:1 to double-masked treatment with LBN once daily (qd) or timolol twice daily (bid) for 3 months followed by open-label LBN treatment for 3 (LUNAR) or 9 (APOLLO) months...
November 30, 2017: Journal of Glaucoma
keyword
keyword
26347
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"